News | January 23, 2026
Dr Reddys Laboratories consolidated Q3 FY26 PAT drops to Rs. 1209.8 Cr, expands global pipeline
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
Subscribe To Our Newsletter & Stay Updated
